The Human Disharmony Loop Clinical Presentation. by James M. Friedman (22522150)

The Human Disharmony Loop (central). by James M. Friedman (22522150)

This is the raw data used for this study. by James M. Friedman (22522150)

“…Average age was 48. 37% were male. 89% of patients who received a preoperative subcoracoid injection reported a significant decrease in presenting symptoms. 6 months after PM release, median VAS pain scores decreased from 8 to 2. …”

Pre-operative versus post-operative symptoms. by James M. Friedman (22522150)

“…Average age was 48. 37% were male. 89% of patients who received a preoperative subcoracoid injection reported a significant decrease in presenting symptoms. 6 months after PM release, median VAS pain scores decreased from 8 to 2. …”

Patient Demographics. by James M. Friedman (22522150)

“…Average age was 48. 37% were male. 89% of patients who received a preoperative subcoracoid injection reported a significant decrease in presenting symptoms. 6 months after PM release, median VAS pain scores decreased from 8 to 2. …”

Diagnostic Criteria for Human Disharmony Loop. by James M. Friedman (22522150)

“…Average age was 48. 37% were male. 89% of patients who received a preoperative subcoracoid injection reported a significant decrease in presenting symptoms. 6 months after PM release, median VAS pain scores decreased from 8 to 2. …”

General procedure for the synthesis of Kylo-0603. by Xueqin lu (22250795)

Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combine... by Xueqin lu (22250795)

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. by Xueqin lu (22250795)

General procedure for the synthesis of B. by Xueqin lu (22250795)

The trends of cholesterol metabolism-related gene expression in liver tissue. by Xueqin lu (22250795)

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

¹³C NMR spectra for Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

Synthesis process of Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”